A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA ® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% in patients with a

Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care

Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection BRIDGEWATER, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- JAMA Network Open has

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday,

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40 th Annual J.P.

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body of